表紙
市場調査レポート

インドの医薬品市場の予測:治療領域の成長と主要企業の将来見通し

Indian Pharmaceutical Market Forecast 2016-2026: Future Prospects for Leading Companies in Generics, OTC, Originator Products and Biosimilars Propelled by Growth in Key Therapeutic Areas

発行 Visiongain Ltd 商品コード 346223
出版日 ページ情報 英文 194 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=137.27円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
インドの医薬品市場の予測:治療領域の成長と主要企業の将来見通し Indian Pharmaceutical Market Forecast 2016-2026: Future Prospects for Leading Companies in Generics, OTC, Originator Products and Biosimilars Propelled by Growth in Key Therapeutic Areas
出版日: 2015年12月01日 ページ情報: 英文 194 Pages
概要

インドの医薬品市場の総収益は、2020年に361億8千万米ドルに達すると予測されています。

当レポートでは、インドの医薬品市場について調査分析し、収益予測、主要企業の評価、促進要因・抑制要因、見通しなど、体系的な情報を提供しています。

第1章 レポートの概要

第2章 インドの医療:概要

  • インド:人口統計指標の概要
  • インドの医療制度:概要
  • インドの医療費の分析
  • 当局によるインドの医薬品市場の規制

第3章 インドの医薬品市場:考察と予測

  • 世界第3位の市場 (数量別)
  • 総収益の予測

第4章 インドにおける医療の必要性

  • 有病率
  • 発症率
  • 死亡率

第5章 インドの医薬品市場:主な治療領域

  • 主な治療領域:概要
  • 主な治療領域の予測
  • 感染症
  • 心血管
  • 胃腸
  • 呼吸器
  • 疼痛緩和/鎮痛剤
  • 糖尿病
  • ビタミン/ミネラル/栄養
  • 皮膚科
  • 中枢神経系
  • 婦人科
  • その他

第6章 インドの医薬品市場:主な薬剤の種類

  • 薬剤の種類:概要
  • 薬剤の種類の成長予測
  • ジェネリック医薬品
  • OTC医薬品
  • 特許医薬品
  • バイオシミラー医薬品

第7章 インドの医薬品市場における主要企業

  • 市場概要
  • 上位50社
  • Sun Pharmaceuticals Industries Limited
  • Abbott Healthcare Private Limited (Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Limited. India
  • Lupin

第8章 インドの医薬品市場の定性分析

  • インドの医薬品市場:促進要因・抑制要因
  • SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
  • ファイブフォース分析

第9章 結論

第10章 用語集

図表

目次
Product Code: PHA0079

What can be expected from the Indian Pharmaceutical market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.

Our 194-page report provides 117 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of the Indian pharmaceutical market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter's Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and indications

How will submarkets perform to 2026? Our study forecasts revenues in the following Indian Pharmaceutical submarkets:

  • Generic Drugs
  • Over-The-Counter (OTC) Drugs
  • Patented Drugs
  • Biosimilars

See revenue forecasts for the leading therapeutic areas

How will leading therapeutic areas perform to 2026? Our study forecasts revenues in therapeutic areas including:

  • Infectious disease drugs
  • Cardiovascular disease drugs
  • Gastro-intestinal drugs
  • Respiratory disease
  • Pain relief / analgesics
  • Diabetes
  • Vitamins / Minerals / Nutrients
  • Dermatology
  • Central Nervous System (CNS)
  • Gynaecology

Leading companies and potential for market growth

Overall revenue for the Indian Pharmaceutical market will reach $36.18bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. An ageing population, increasing access to healthcare and increasing incidence of chronic diseases, especially diabetes and cardiovascular disease, will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain's analysis of leading companies, including these:

  • Sun Pharmaceutical Industries Limited
  • Abbott Healthcare Private Limited (Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited (GSK India)
  • Pfizer Limited. India
  • Lupin Pharmaceuticals, Inc.,

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook
  • Historic revenue, analysis and discussion of company performance over the past 10 years
  • Analysis of major products currently on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect Indian pharmaceutical industry?

Our new report discusses issues and events affecting the Indian pharmaceutical market. You will find discussions, including qualitative analyses:

  • Highly diverse market needing strong knowledge of key therapeutic indications
  • Changing regulatory landscape challenging new entrants and major market players alike
  • Emerging drug types with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Indian Pharmaceutical Market Forecast 2015-2026 report helps you

In summary, our 194-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Indian Pharmaceutical market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for each major submarket - discover prospects for leading pharmaceutical products in the following areas: Infectious disease drugs, Cardiovascular disease drugs, Gastro-intestinal drugs, Respiratory disease , Pain relief / analgesics, Diabetes, Vitamins / Minerals / Nutrients, Dermatology, Central Nervous System (CNS), Gynaecology
  • Revenue forecasts to 2026 for the leading drug types - generics, OTC products, patented drugs and biosimilars
  • Assessment of leading companies - analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the indian pharmaceutical market and leading companies. You will find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. The Indian Pharmaceutical Market Overview
  • 1.2. Indian Pharmaceutical Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. Indian Healthcare: Overview

  • 2.1. India: Demographic Indicators Overview
  • 2.2. Indian Healthcare system: Overview
    • 2.2.1. Rashtriya Swasthya Bima Yojana - Bringing Healthcare Coverage to India's Poorest Workers
  • 2.3. Analysis of India's Healthcare Expenditure
  • 2.4. State Bodies regulating the Indian Pharmaceutical Market
    • 2.4.1. The Drugs and Cosmetics Act, 1940

3. Indian Pharmaceutical Market: Discussions and Predictions 2016-2026

  • 3.1. Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume, 2015
  • 3.2. Indian Pharmaceutical Market: Overall Revenue Forecast 2016-2026

4. Medical Treatment Needs in India, 2016-2026

  • 4.1. Disease Prevalence in India, 2016-2026
  • 4.2. Disease Incidence in India, 2016-2026
  • 4.3. Disease Mortality Rates in India, 2016-2026
    • 4.3.1. Top Causes of Death in India
    • 4.3.2. Top Causes of Death in India: Mortality Projections, 2016-2026

5. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2016-2026

  • 5.1. Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2015
  • 5.2. Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2016-2026
  • 5.3. Infectious Disease Therapeutics: Overview, 2015
    • 5.3.1. Infectious Disease Drugs Market: Forecast, 2016-2026
    • 5.3.2. Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2015
    • 5.3.3. Lower Respiratory Tract Infections Among Leading Causes of Death in 2015
    • 5.3.4. Tuberculosis Still Rife in India
    • 5.3.5. Malaria, Risk and Opportunity
    • 5.3.6. HIV in India: Growing Therapeutic Area Worth Watching
    • 5.3.7. Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment, 2015-2026
  • 5.4. Cardiovascular Therapeutic Segment: Overview, 2015
    • 5.4.1. Cardiovascular Disease - India's Leading Cause of Death, 2015
    • 5.4.2. Cardiovascular Drugs Market: Forecast, 2016-2026
    • 5.4.3. Drivers and Restraints for the Indian Cardiovascular Drugs Market, 2015-2026
  • 5.5. Gastro-Intestinal Therapeutic Segment: Overview, 2015
    • 5.5.1. Gastro-Intestinal Drugs Market: Forecast, 2016-2026
    • 5.5.2. Gastro-Intestinal Drugs in India: Challenges and Opportunities
    • 5.5.3. Drivers and Restraints for the Gastro-Intestinal Drugs Segment, 2015
  • 5.6. Respiratory Therapeutic Segment: Overview, 2015
    • 5.6.1. Respiratory Disease Drugs Market: Forecast, 2016-2026
    • 5.6.2. Drivers and Restraints for the Respiratory Diseases Segment, 2015
  • 5.7. Pain Relief / Analgesics Therapeutic Segment: Overview, 2015
    • 5.7.1. Pain Relief / Analgesics Drugs Market: Forecast, 2016-2026
    • 5.7.2Drivers and Restraints for the Pain Relief / Analgesics Drugs Segment, 2015
  • 5.8. Diabetes Therapeutic Segment: Overview, 2015
    • 5.8.1. Diabetes Drugs Market: Forecast, 2016-2026
    • 5.8.2. Drivers and Restraints for the Diabetes Drugs Segment, 2015
  • 5.9. Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2015
    • 5.9.1. Vitamins / Minerals / Nutrients Drugs Market: Forecast, 2016-2026
    • 5.9.2. Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
    • 5.9.3. Drivers and Restraints for the Vitamins / Minerals / Nutrients Drugs Segment, 2015
  • 5.10. Dermatological Therapeutic Segment: Overview, 2015
    • 5.10.1. Dermatological Drugs Market: Forecast, 2016-2026
    • 5.10.2. Drivers and Restraints for the Dermatological Drugs Segment, 2015
  • 5.11. Central Nervous System (CNS) Therapeutics: Overview, 2015
    • 5.11.1. CNS Drugs Market: Forecast, 2016-2026
    • 5.11.2. Intentional Injury Among the Top 10 Leading Causes of Death, 2015:
    • 5.11.3. India's Aging Population: Driver for the CNS Segment
    • 5.11.4. Drivers and Restraints for the CNS Drugs Segment, 2015
  • 5.12. Gynaecological Treatment Market Overview: 2015
    • 5.12.1. Infant Mortality Still High in India
    • 5.12.2. Indian Gynaecological Treatments Market: Forecast, 2016-2026
    • 5.12.3. Drivers and Restraints for the Gynaecological Segment, 2015
  • 5.13. Other Pharmaceutical Products Market Overview: 2015
    • 5.13.1. Incidence of Cancer in India is Rising
    • 5.13.2. Indian Other Treatments Market: Forecast, 2016-2026

6. Indian Pharmaceutical Market: Leading Drug Types, 2016-2026

  • 6.1. Drug Types in the Indian Market: Overview, 2015
  • 6.2. Growth Forecasts for Leading Drug Types in India, 2016-2026
  • 6.3. Generic Drugs Dominate the Indian Pharmaceutical Market
    • 6.3.1. Indian Generics: Overview, 2015
    • 6.3.2. Indian Generic Drugs Market: Forecast, 2016-2026
    • 6.3.3. Branded Generics Preferred by Many Indian Patients
    • 6.3.4. Drivers and Restraints for the Generic Drug Market in India, 2015
  • 6.4. Indian Over-The-Counter (OTC) Drugs Market: Overview, 2015
    • 6.4.1. Indian OTC Market: Forecast, 2016-2026
    • 6.4.2. Drivers and Restraints of the Indian OTC Market
  • 6.5. Indian Patented Drugs Market: Overview, 2015
    • 6.5.1. Indian Patented Drugs Market: Forecasts, 2016-2026
    • 6.5.2. Drivers and Restraints for the Indian Patented Drugs Market
  • 6.6. Indian Biosimilar Drugs, 2015
    • 6.6.1. Indian Biosimilar Drugs Market: Forecast, 2016-2026
    • 6.6.2. A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
    • 6.6.3. Drivers and Restraints of the Indian Biosimilar Drugs Market

7. The Leading Companies in the Indian Pharmaceutical Market, 2016-2026

  • 7.1. Indian Pharmaceutical Market Overview
    • 7.1.1. Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
  • 7.2. Top 50 Domestic Indian Pharmaceutical Companies, 2015
  • 7.3. Sun Pharmaceuticals Industries Limited
    • 7.3.1. Sun Pharma: Global Presence
      • 7.3.1.1. Sun Pharmaceutical Sales by Region, 2015
    • 7.3.2. Sun Pharmaceuticals Business Performance 2006-2015
    • 7.3.3. Sun Pharmaceutical: Ranbaxy Laboratories Acquisition is the Largest Ever Deal Made by an Indian Pharmaceutical Company
      • 7.3.3.1. Other Major M&A Activity
  • 7.4. Abbott Healthcare Private Limited (Abbott India)
    • 7.4.1. Abbott India: Business Performance 2006-2015
    • 7.4.2. Abbott India: Key Brands in the Indian Pharmaceutical Market
    • 7.4.3. Abbott India: Major and Recent M&A Activity
  • 7.5. Cipla Ltd.
    • 7.5.1. Cipla: Business Performance 2006-2015
  • 7.6. Cadila Healthcare Limited
    • 7.6.1. Cadila: Business Performance 2006-2015
    • 7.6.2. Cadila Healthcare Revenue by Therapeutic Area 2015
    • 7.6.3. Cadila Healthcare Revenue by Business Area 2015
  • 7.7. GlaxoSmithKline Pharmaceuticals Limited
    • 7.7.1. GlaxoSmithKline India: Business Performance 2006-2015
    • 7.7.2. GlaxoSmithKline India: Revenue by Product Type, 2015
  • 7.8. Pfizer Limited. India
    • 7.8.1. Pfizer India: Business Performance 2006-2015
    • 7.7.2. Pfizer India: Revenue by Product Type, 2015
  • 7.9. Lupin
    • 7.9.1. Lupin: Business Performance 2006-2015
    • 7.9.2. Lupin Revenue by Therapeutic Area, 2015

8. Qualitative Analysis of the Indian Pharmaceutical Market, 2015

  • 8.1. Indian Pharmaceutical Market: Drivers and Restraints
  • 8.2. SWOT Analysis of the Indian Pharmaceutical Market, 2015-2026
  • 8.3. Strengths
    • 8.3.1. Increasing Investment in the Healthcare System
    • 8.3.2. The Disease Burden and GDP Both Growing
    • 8.3.3. India's Population Set to Become the World's Largest by 2030
    • 8.3.4. India Popular for Pharmaceutical Outsourcing
  • 8.4. Weaknesses
    • 8.4.1. Stringent Pricing Regulations Hit the Indian Pharmaceutical Market
    • 8.4.2. Poor Infrastructure Threatens to Hinder Market Potential
    • 8.4.3. Intense Competition Driving Down Drug Prices
  • 8.5. Opportunities
    • 8.5.1. Global Demand for Generics Rising
    • 8.5.2. National Rural Health Mission Driving Healthcare Access in Rural Areas
    • 8.5.3. Significant Investment from MNCs Expected
    • 8.5.4. Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
  • 8.6. Threats
    • 8.6.1. Rise of Other Low-Cost Generic Exporters
    • 8.6.2. Will the Indian Government Stick to Increasing Healthcare Expenditure?
    • 8.6.3. Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
  • 8.7. Porter's Five Forces Analysis of the Indian Pharmaceutical Market
    • 8.7.1. Rivalry Among Competitors [High]
    • 8.7.2. Threat of New Entrants [Low]
    • 8.7.3. Power of Suppliers [Medium]
    • 8.7.4. Power of Buyers [High]
    • 8.7.5. Threat of Substitutes [Low]

9. Conclusion

  • 9.1. The Indian Pharmaceutical Market: Growing Global Market Share
  • 9.2. Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
  • 9.3. Commercial Drivers of the Indian Pharmaceutical Market
  • 9.4. Commercial Restraints of the Indian Pharmaceutical Market
  • 9.5. Concluding Remarks

10. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 1.1: Rupee to Dollar Historical Exchange Rates 2006-2015
  • Table 1.2: The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2015-2026
  • Table 3.1: The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.1: Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Table 4.2: Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
  • Table 4.3: Causes of Death in India by World Ranking, 2014
  • Table 5.1: Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2015, 2020, 2026
  • Table 5.2: The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2015-2026
  • Table 5.3: The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.4: The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.5: The Indian Gastro-Intestinal Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.6: The Indian Respiratory Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.7: The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.8: The Indian Diabetes Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.9: The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.10: The Indian Dermatological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.11: The Indian CNS Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.12: The Indian Gynaecological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.13: The Indian Other Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 6.1: Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2015, 2020 and 2026
  • Table 6.2: The Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2015-2026
  • Table 6.3: The Indian Generic Drug Market: Revenue ($bn), AGR (%) and CAGR (%) 2015-2026
  • Table 6.4: The Indian OTC Drug Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 6.5: The Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 6.6: Selected Biosimilar Therapeutics on the Indian Market, 2015
  • Table 6.7: Selected Biosimilar Therapeutics on the Indian Market, 2015 (continued)
  • Table 6.8: The Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 6.9: Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
  • Table 6.10: Selected Late-Stage Biosimilar Pipeline Products, 2015
  • Table 7.1: Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs.m), Revenue ($m) and Market Share (%), 2015
  • Table 7.2: Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2006, 2010 and 2015
  • Table 7.3: Sun Pharmaceuticals: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Business Area, 2015
  • Table 7.4: Sun Pharmaceuticals: Revenue (Rs.m), Revenue ($m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.5: Sun Pharmaceuticals: M&A Activity, 1997-2015
  • Table 7.6: Abbott India: Market Share (%) and Market Rank of Key Brands
  • Table 7.7: Abbott India: Revenue (Rs.m), Revenue ($m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.8: Abbott India: Key Products in India, Market Share (%) and Rank, 2015
  • Table 7.9: Abbott India: Key Products in India, Market Share (%) and Rank, 2015 (continued)
  • Table 7.10: Cipla: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.11: Cipla: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2015
  • Table 7.12: Cadila Healthcare Ltd.: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.13: Cadila Healthcare Ltd.: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Therapeutic Area, 2015
  • Table 7.14: Cadila Healthcare Ltd.: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Business Area, 2015
  • Table 7.15: GlaxoSmithKline India: Key Products in the Indian Market, 2015
  • Table 7.16: GlaxoSmithKline India: Key Products in the Indian Market, 2015 (continued)
  • Table 7.17: GlaxoSmithKline India Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.18: GlaxoSmithKline India: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Product Type, 2015
  • Table 7.19: Pfizer India: Leading Brands on the Indian Market 2015
  • Table 7.20: Pfizer India: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.21: Pfizer India: Revenue (Rs.m), Revenue ($m) and Revenue Share (%) by Product Type, 2015
  • Table 7.22: Lupin: Total Revenue (Rs.m), Total Revenue ($m), AGR (%) and CAGR (%), 2006-2015
  • Table 7.23: Lupin: Revenue Share (%) by Therapeutic Area, 2015
  • Table 7.24: Growth of Top Brands (%), by Therapeutic Area, 2015
  • Table 8.1: SWOT Analysis of the Indian Pharmaceutical Market, 2015-2026

List of Figures

  • Figure 1.1: Indian Pharmaceutical Market: Overview of Submarkets
  • Figure 2.1: Indian Population: Rural and Urban Populations (bn) and Percent of Population in Urban Areas (%), 1980-2015
  • Figure 2.2: Indian Population: Total Population (bn) and Annual Population Growth Rate (%), 2006-2014
  • Figure 2.3: Indian GDP ($bn) and GDP growth (%), 2006-2014
  • Figure 2.4: Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2006-2015
  • Figure 2.5: Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2013
  • Figure 2.6: Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2006-2013
  • Figure 3.1: The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 4.1: Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Figure 5.1: Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2015
  • Figure 5.2: Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2020
  • Figure 5.3: Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2026
  • Figure 5.4: The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.5: Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
  • Figure 5.6: Infectious Disease Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.7: The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.8: Cardiovascular Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.9: The Indian Gastro-Intestinal Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.10: Gastro-intestinal Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.11: The Indian Respiratory Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.12: Respiratory Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.13: The Indian Pain Relief / Analgesics Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.14: Pain Relief / Analgesics Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.15: The Indian Diabetes Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.16: Diabetes Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.17: The Indian Vitamins / Minerals / Nutrients Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.18: Vitamins / Minerals / Nutrients Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.19: The Indian Dermatological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.20: Dermatological Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.21: The Indian CNS Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.22: CNS Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.23: The Indian Gynaecological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.24: Gynaecological Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 5.25: The Indian Other Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 6.1: Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2015
  • Figure 6.2: Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2020
  • Figure 6.3: Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2026
  • Figure 6.4: The Indian Generic Drug Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 6.5: Generic Drug Market in India: Drivers and Restraints, 2015-2026
  • Figure 6.6: The Indian OTC Drug Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 6.7: OTC Drug Market in India: Drivers and Restraints, 2015-2026
  • Figure 6.8: The Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 6.9: Patented Drugs Market in India: Drivers and Restraints, 2015-2026
  • Figure 6.10: The Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 6.11: Biosimilar Drug Market in India: Drivers and Restraints, 2015-2026
  • Figure 7.1: Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2006
  • Figure 7.2: Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2010
  • Figure 7.3: Sun Pharmaceuticals: Revenue Share (%) by Business Area, 2015
  • Figure 7.4: Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2006-2015
  • Figure 7.5: Abbott India: Revenue ($m) and AGR (%), 2006-2015
  • Figure 7.6: Cipla Revenue ($m) and AGR (%), 2006-2015
  • Figure 7.7: Cipla: Revenue Share (%) by Geographical Area, 2015
  • Figure 7.8: Cadila Healthcare Ltd.: Revenue ($m) and AGR (%), 2006-2015
  • Figure 7.9: Cadila Healthcare Ltd.: Revenue Share (%) by Business Area, 2015
  • Figure 7.10: Cadila Healthcare Ltd.: Revenue Share (%) by Business Area, 2015
  • Figure 7.11: GlaxoSmithKline India: Revenue ($m) and AGR (%), 2006-2015
  • Figure 7.12: GlaxoSmithKline India: Revenue Share (%) by Product Type, 2015
  • Figure 7.13: Pfizer India: Revenue ($m) and AGR (%), 2006-2015
  • Figure 7.14: Pfizer India: Revenue Share (%) by Product Type, 2015
  • Figure 7.15: Lupin: Revenue ($m) and AGR (%), 2006-2015
  • Figure 7.16: Lupin: Revenue Share (%) by Therapeutic Area, 2015
  • Figure 8.1: Indian Pharmaceutical Market: Drivers and Restraints, 2015-2026
  • Figure 8.2: Porter's Five Forces Analysis of the Indian Pharmaceuticals Market, 2016-2026

Companies Listed

  • Sun Pharmaceuticals Industries Ltd
  • Abbott India
  • Cipla
  • Cadila Healthcare Ltd.
  • Mankind
  • Alkem
  • GSK India
  • Macleods
  • Pfizer India
  • Lupin
  • Intas Pharma
  • Torrent Pharma
  • Emcure
  • Sanofi India
  • Aristo Pharma
  • Dr Reddy's Labs
  • Glenmark Pharma
  • USV
  • Micro Labs
  • Alembic
  • Novartis India
  • Ipca Labs
  • Wockhardt
  • FDC
  • Unichem
  • MSD Pharma
  • Cadila Pharma
  • Merck KGaA
  • Franco India
  • Indoco
  • Eris Lifesciences
  • The Himalaya Drug Company
  • Divis Laboratories
  • Blue Cross Laboratories Ltd.
  • JB Chemicals
  • Bharat Serums
  • AstraZeneca
  • Meyer Organics
  • Raptakos, Brett & Co. Ltd
  • Akumentis Healthcare Ltd
  • Hetero Drugs Ltd
  • Wallace + Indi Pharma
  • Medley Pharmaceuticals Ltd
  • Janssen
  • Win-Medicare
  • Fourrts (India) Laboratories Pvt, Ltd
  • Ajanta Pharma Ltd
  • Biocon Ltd
  • Apex Laboratories Pvt. Ltd
  • Albert David Ltd
  • Claris Lifesciences
  • Lonza
  • Bayer
  • Natco
  • Shantha Biotechnics
  • Merieux Alliance
  • Gennova Biopharmaceuticals
  • Virchow Biotech
  • Bioviz Technologies
  • Gland Pharma
  • Serum Institute of India
  • Zenotech Laboratories
  • Epirus Biopharmaceuticals
  • Sandoz (Novartis)
  • Novartis
  • Caraco Pharmaceutical Laboratories
  • Able Labs
  • Cattern Chemical Inc.
  • DUSA Pharmaceuticals Inc.
  • Intrexon
  • URL
  • Merck
  • Pharmalucence
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Ltd.
  • Daiichi Sankyo
  • Piramal Healthcare
  • Sanofi
  • Cadila Pharmaceuticals Ltd.
  • Medpro Pharmaceutica (Pty) Ltd.
  • Megafine Pharma
  • Novo Nodisk

Organisations Mentioned in the Report

  • Central Drugs Standard Control Organisation (CDSCO)
  • Competition Commission of India (CCI)
  • Drug Technical Advisory Board (DTAB)
  • Drug Consultative Committee (DCC)
  • European Medicines Agency
  • High Court of Punjab and Haryana
  • Indian Patent Office
  • (Japan's) Minstry of Health, Labour and Welfare (MHLW)
  • Medical Council of India
  • (Indian) Ministry of Health
  • National AIDS Control Organisation (NACO)
  • (Australia's) Therapeutic Goods Administration (TGA)
  • UK Medicines & Healthcare Products Regulatory Agency (MHRA)
  • US Federal Trade Commission (FTC)
  • US Food and Drug Administration (FDA)
  • UNAIDS
  • World Bank
  • World Health Organisation (WHO)
  • World Trade Organisation (WTO)
Back to Top